Clinical Trial Update: Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and immunogenicity of HEPLISAV for adults on hemodialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• HEPLISAV (hepatitis B vaccine)

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: End Stage Renal Disease | Phase 3 | Status: COMPLETED